EcoDrugPlus

60s Ribosomal Protein L9

Ensembl ID : ENSLBEG00000023234
Gene Symbol: LOC109975369
3 Cross references
508 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSLBEG00000019337
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSLBEG00000020511
Gene Symbol: ADAM17
3 Cross references
209 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSLBEG00000015086
Gene Symbol: ADAM17
3 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSLBEG00000024924
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSLBEG00000014791
Gene Symbol: ADRM1
3 Cross references
191 Possible Orthologues:

Akt Serine/threonine Kinase 1

Ensembl ID : ENSLBEG00000026110
Gene Symbol: AKT1
3 Cross references
195 Possible Orthologues:

Alk Tyrosine Kinase Receptor-Like

Ensembl ID : ENSLBEG00000020594
Gene Symbol: LOC109990866
2 Cross references
193 Possible Orthologues:

Atp Binding Cassette Subfamily C Member 8

Ensembl ID : ENSLBEG00000003141
Gene Symbol: ABCC8
3 Cross references
225 Possible Orthologues:

Atp-Binding Cassette Sub-Family C Member 9-Like

Ensembl ID : ENSLBEG00000010166
Gene Symbol: LOC110004529
2 Cross references
239 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 1

Ensembl ID : ENSLBEG00000025529
Gene Symbol: ATP1B1
3 Cross references
225 Possible Orthologues:

Atpase Na+/k+ Transporting Subunit Beta 2

Ensembl ID : ENSLBEG00000017508
Gene Symbol: ATP1B2
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).